Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant_老虎社区_美港股上老虎

Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant

TheStreet2021-11-29

Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant. Pfizer shares extended ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

2020TS
·2021-11-30
Get your price correct, $530/tablet, it's day light robbery.
回复
点赞
举报
收起
- Ahwinwin:
  This is crazy
  2021-12-02
  回复
  举报
admaris
·2021-11-29
nice
回复
点赞
举报
Ahwinwin
·2021-11-29
Gogogo!! Vaccines pls…
回复
1
举报
收起
- Ahwinwin:
  Why its not going up?
  2021-12-19
  回复
  举报
- Ahwinwin:
  More vaccines pls
  2021-12-05
  回复
  举报
- Ahwinwin:
  Why is it going down?
  2021-12-01
  回复
  举报
Justin8991
·2021-11-29
Ok
回复
1
举报
Patek1975
·2021-11-29
To the moon we go
回复
2
举报
MrInvestor
·2021-11-29
Pfizer will still grow and grow
回复
6
举报
收起
- theunmouse:
  Ok
  2021-11-29
  回复
  举报
- Yonakazuk:
  Buy buy buy!
  2021-11-29
  回复
  举报
- Investcub:
  Agreed!!!
  2021-11-29
  回复
  举报
FlorCheah
·2021-11-29
PFE
回复
4
举报
收起
- KCNG:
  Ok
  2021-11-29
  回复
  举报
supergrowth
·2021-11-29
Buy.
回复
8
举报
收起
- MrInvestor:
  yes
  2021-11-29
  回复
  举报
- SmallYang:
  but quite pricey now
  2021-11-29
  回复
  举报
- JAMKKT:
  Ok
  2021-11-29
  回复
  举报
Rteo
·2021-11-29
Covid related stocks are back again
回复
6
举报
收起
- KLS:
  Buy
  2021-11-29
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1188274579?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-29 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188274579","market":"us","top_or_hot":-1,"title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","media":"TheStreet","content":"<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","article_id":"1188274579","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","pubTimestamp":1638192806,"sourceInfo":null,"weMediaInfo":null,"summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","collect":0,"end_time":0,"defaultTopTitle":"thestreet.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"辉瑞股价上涨，计划提高Covid药丸产量，以对抗奥米克隆变体","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9},"content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":609989381,"gmtCreate":1638231322546,"gmtModify":1638231323053,"author":{"id":"3568580098685907","authorId":"3568580098685907","name":"2020TS","avatar":"https://static.tigerbbs.com/dc251ae3d7264077ed6557978fbfc6bb","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3568580098685907","authorIdStr":"3568580098685907"},"htmlText":"Get your price correct, $530/tablet, it's day light robbery.","listText":"Get your price correct, $530/tablet, it's day light robbery.","text":"Get your price correct, $530/tablet, it's day light robbery.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609989381","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6817866,"gmtCreate":1638458859058,"gmtModify":1638458859088,"authorId":3581581482227808,"author":{"id":3581581482227808,"idStr":"3581581482227808","authorId":3581581482227808,"name":"Ahwinwin","avatar":"https://static.tigerbbs.com/3c07e1f8dddb5aaa5c34d12a8c916a54","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609989381,"type":1,"supId":0,"prevId":0,"content":"This is crazy","text":"This is crazy","html":"This is crazy"}],"langContent":"CN"},{"id":600761941,"gmtCreate":1638198483826,"gmtModify":1638198483969,"author":{"id":"4098950502646600","authorId":"4098950502646600","name":"admaris","avatar":"https://static.tigerbbs.com/f1ce3d6f8a55a5fe565e8e4779bf5174","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4098950502646600","authorIdStr":"4098950502646600"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600761941","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":600792009,"gmtCreate":1638196562154,"gmtModify":1638196562379,"author":{"id":"3581581482227808","authorId":"3581581482227808","name":"Ahwinwin","avatar":"https://static.tigerbbs.com/3c07e1f8dddb5aaa5c34d12a8c916a54","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581581482227808","authorIdStr":"3581581482227808"},"htmlText":"Gogogo!! Vaccines pls…","listText":"Gogogo!! Vaccines pls…","text":"Gogogo!! Vaccines pls…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/600792009","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7045761,"gmtCreate":1639929561339,"gmtModify":1639929561367,"authorId":3581581482227808,"author":{"id":3581581482227808,"idStr":"3581581482227808","authorId":3581581482227808,"name":"Ahwinwin","avatar":"https://static.tigerbbs.com/3c07e1f8dddb5aaa5c34d12a8c916a54","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600792009,"type":1,"supId":0,"prevId":0,"content":"Why its not going up?","text":"Why its not going up?","html":"Why its not going up?"},{"id":6856900,"gmtCreate":1638715592511,"gmtModify":1638715592601,"authorId":3581581482227808,"author":{"id":3581581482227808,"idStr":"3581581482227808","authorId":3581581482227808,"name":"Ahwinwin","avatar":"https://static.tigerbbs.com/3c07e1f8dddb5aaa5c34d12a8c916a54","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600792009,"type":1,"supId":0,"prevId":0,"content":"More vaccines pls","text":"More vaccines pls","html":"More vaccines pls"},{"id":6801102,"gmtCreate":1638368411974,"gmtModify":1638368411999,"authorId":3581581482227808,"author":{"id":3581581482227808,"idStr":"3581581482227808","authorId":3581581482227808,"name":"Ahwinwin","avatar":"https://static.tigerbbs.com/3c07e1f8dddb5aaa5c34d12a8c916a54","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600792009,"type":1,"supId":0,"prevId":0,"content":"Why is it going down?","text":"Why is it going down?","html":"Why is it going down?"}],"langContent":"CN"},{"id":600704073,"gmtCreate":1638196038413,"gmtModify":1638196038600,"author":{"id":"3575292984950927","authorId":"3575292984950927","name":"Justin8991","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575292984950927","authorIdStr":"3575292984950927"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600704073","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":600702936,"gmtCreate":1638195889446,"gmtModify":1638195889767,"author":{"id":"3566293775093626","authorId":"3566293775093626","name":"Patek1975","avatar":"https://static.tigerbbs.com/a2e5f9a5d563704aaf5f2473be16f148","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566293775093626","authorIdStr":"3566293775093626"},"htmlText":"To the moon we go","listText":"To the moon we go","text":"To the moon we go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600702936","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":600470353,"gmtCreate":1638193964055,"gmtModify":1638193964679,"author":{"id":"3586672191897597","authorId":"3586672191897597","name":"MrInvestor","avatar":"https://static.tigerbbs.com/40974a38cd623c0089adf8fd12d91591","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586672191897597","authorIdStr":"3586672191897597"},"htmlText":"Pfizer will still grow and grow","listText":"Pfizer will still grow and grow","text":"Pfizer will still grow and grow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/600470353","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6771479,"gmtCreate":1638196125068,"gmtModify":1638196125163,"authorId":3572018203797244,"author":{"id":3572018203797244,"idStr":"3572018203797244","authorId":3572018203797244,"name":"theunmouse","avatar":"https://static.tigerbbs.com/c336181da66212b3d13c0ea59b6f69b5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600470353,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6771217,"gmtCreate":1638194925764,"gmtModify":1638194925796,"authorId":3582348929679840,"author":{"id":3582348929679840,"idStr":"3582348929679840","authorId":3582348929679840,"name":"Yonakazuk","avatar":"https://static.tigerbbs.com/2692aaa50828068617038f2be6a6b9de","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600470353,"type":1,"supId":0,"prevId":0,"content":"Buy buy buy!","text":"Buy buy buy!","html":"Buy buy buy!"},{"id":6771095,"gmtCreate":1638194475340,"gmtModify":1638194475371,"authorId":3584582153384625,"author":{"id":3584582153384625,"idStr":"3584582153384625","authorId":3584582153384625,"name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600470353,"type":1,"supId":0,"prevId":0,"content":"Agreed!!!","text":"Agreed!!!","html":"Agreed!!!"}],"langContent":"CN"},{"id":600447924,"gmtCreate":1638193864835,"gmtModify":1638193865474,"author":{"id":"3573025586175142","authorId":"3573025586175142","name":"FlorCheah","avatar":"https://static.tigerbbs.com/8cb91e5f44e414335718e1beffda39e8","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573025586175142","authorIdStr":"3573025586175142"},"htmlText":"PFE","listText":"PFE","text":"PFE","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600447924","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6771464,"gmtCreate":1638196032188,"gmtModify":1638196032296,"authorId":3564539038897071,"author":{"id":3564539038897071,"idStr":"3564539038897071","authorId":3564539038897071,"name":"KCNG","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600447924,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"CN"},{"id":600443485,"gmtCreate":1638193062251,"gmtModify":1638193062438,"author":{"id":"3581854803062408","authorId":"3581854803062408","name":"supergrowth","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581854803062408","authorIdStr":"3581854803062408"},"htmlText":"Buy.","listText":"Buy.","text":"Buy.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/600443485","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6770972,"gmtCreate":1638193821370,"gmtModify":1638193821473,"authorId":3586672191897597,"author":{"id":3586672191897597,"idStr":"3586672191897597","authorId":3586672191897597,"name":"MrInvestor","avatar":"https://static.tigerbbs.com/40974a38cd623c0089adf8fd12d91591","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600443485,"type":1,"supId":6770922,"prevId":0,"content":"yes","text":"yes","html":"yes"},{"id":6770922,"gmtCreate":1638193583497,"gmtModify":1638193583535,"authorId":4088082610944870,"author":{"id":4088082610944870,"idStr":"4088082610944870","authorId":4088082610944870,"name":"SmallYang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600443485,"type":1,"supId":0,"prevId":0,"content":"but quite pricey <u>now</u>","text":"but quite pricey <u>now</u>","html":"but quite pricey <u>now</u>"},{"id":6770905,"gmtCreate":1638193520194,"gmtModify":1638193520222,"authorId":3580120666305176,"author":{"id":3580120666305176,"idStr":"3580120666305176","authorId":3580120666305176,"name":"JAMKKT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600443485,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":600443227,"gmtCreate":1638193039699,"gmtModify":1638193645748,"author":{"id":"3582595806100338","authorId":"3582595806100338","name":"Rteo","avatar":"https://static.tigerbbs.com/ba4c61a94c707cd25f18400b8cc52a4c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582595806100338","authorIdStr":"3582595806100338"},"htmlText":"Covid related stocks are back again","listText":"Covid related stocks are back again","text":"Covid related stocks are back again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600443227","repostId":1188274579,"repostType":4,"repost":{"id":"1188274579","pubTimestamp":1638192806,"share":"https://www.laohu8.com/m/news/1188274579?lang=&edition=full","pubTime":"2021-11-29 21:33","market":"us","language":"en","title":"Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant","url":"https://stock-news.laohu8.com/highlight/detail?id=1188274579","media":"TheStreet","summary":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivri","content":"<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.</p>\n<p>Pfizer&nbsp;shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.</p>\n<p>Pfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.</p>\n<p>The antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.</p>\n<p>Bourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding&nbsp; the drugmaker has the capability to make as many as 4 billion doses next year.</p>\n<p>Scientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.</p>\n<p>Pfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.</p>\n<p>Earlier this month,&nbsp;Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food &amp; Drug Administration, to the United States Department of Health and Human Services.</p>\n<p>At $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck &amp; Co. MRK last month to buy&nbsp;1.7 million doses its 'molnupiravir' treatment&nbsp;of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Jumps On Plan To Boost Covid Pill Production In Fight Against Omicron Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 21:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended ...</p>\n\n<a href=\"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/markets/pfizer-stock-jumps-on-covid-pill-production-boost-to-fight-omicron","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188274579","content_text":"Pfizer CEO Albert Bourla confirmed the drugmaker's plans to boost production of its Paxlovid antivrical treatment in the first against the spread of the new Omicron variant.\nPfizer shares extended gains Monday after the drugmaker said it's preparing to boost production of its Covid antiviral treatment to combat the potential impact of the newly-discovered Omicron variant.\nPfizer CEO Albert Bourla told CNBC Monday that the drugmaker has committed to making 80 million doses of Paxlovid, its developing antiviral, up from its prior forecast of 50 million.\nThe antiviral treatment may continue to be an effective defense against the variant, which was first identified in South Africa, even as scientists remain concerned that it may be resistant to both vaccine structures and natural immunity.\nBourla also said that Pfizer has created a new template that could speed the development of a new vaccine to combat Omicron if needed, adding  the drugmaker has the capability to make as many as 4 billion doses next year.\nScientists and health officials have yet to determine if Omicron is vaccine resistant, with the World Health Organization cautioning that it could take \"several weeks\" to assess its full potential.\nPfizer shares were marked 1.85% higher in pre-market trading Monday to indicate an opening bell price of $55.0 each. The stock hit an all-time high of $54.94 in mid-day trading on Friday.\nEarlier this month, Pfizer said it will sell around 10 million of its Paxlovid treatment,which is currently being reviewed for Emergency Use Approval (EUA) by the U.S. Food & Drug Administration, to the United States Department of Health and Human Services.\nAt $530 per tablet, the cost is around 25% cheaper than the $700 price agreed with Merck & Co. MRK last month to buy 1.7 million doses its 'molnupiravir' treatment of \"mild-to-moderate Covid in adults who are at risk for progressing to severe forms of disease, or hospitalization.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6770960,"gmtCreate":1638193771981,"gmtModify":1638193772078,"authorId":3551655093075927,"author":{"id":3551655093075927,"idStr":"3551655093075927","authorId":3551655093075927,"name":"KLS","avatar":"https://static.tigerbbs.com/60fe00969bbce4cfecf0d17a38c77628","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":600443227,"type":1,"supId":0,"prevId":0,"content":"<u>Buy</u>","text":"<u>Buy</u>","html":"<u>Buy</u>"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":94,"commentSize":9,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}